64 results
8-K
EX-10.2
KPRX
Kiora Pharmaceuticals Inc
1 Feb 21
Departure of Directors or Certain Officers
6:55am
shall furthermore receive a one-off "Retention Bonus" for the fiscal year 2021 of EUR 86,000 (Euro eighty six thousand). The "Retention Bonus" shall … is entitled to receive the full amount of the "Retention Bonus".
Item 5. "Employee Pension Fund" shall be renamed, amended and read as follows:
Severance pay
8-K
EX-10.1
KPRX
Kiora Pharmaceuticals Inc
1 Feb 21
Departure of Directors or Certain Officers
6:55am
-first) March of the following fiscal year.
The Managing Director shall furthermore receive a one-off "Retention Bonus" for the fiscal year 2021 … amounting to 40% (forty percent) of his fixed annual salary. The "Retention Bonus" shall in principle be paid in two equal instalments. One half shall
8-K
EX-99.1
KPRX
Kiora Pharmaceuticals Inc
27 May 21
Regulation FD Disclosure
7:01am
with Immune - Modulating Potency Unique and proprietary formulation optimizes solubility and retention on the ocular surface These characteristics … Creates Unique Attributes Ideal for Ocular Surface Prevents degradation, predominately excreted in crosslinked form Much longer retention
8-K
KPRX
Kiora Pharmaceuticals Inc
1 Feb 21
Departure of Directors or Certain Officers
6:55am
. Additionally, Dr. Obermayr will be entitled to receive a retention bonus of €86,000, payable in two equal installments in June 2021 and December 2021
DRS/A
EX-10.10
KPRX
Kiora Pharmaceuticals Inc
8 Jul 14
Draft registration statement (amended)
12:00am
as your Service continues and for such period of time after the termination of your Service as the Company may specify.
Retention Rights
Your award
DRS/A
EX-10.9
qpfwxuj1ei
8 Jul 14
Draft registration statement (amended)
12:00am
DRS/A
EX-10.2
16cjjswnvlc
8 Jul 14
Draft registration statement (amended)
12:00am
8-K
EX-99.1
z1i9zth1x l89l5b
11 Jan 22
Regulation FD Disclosure
12:00am
8-K
EX-99.1
i25frd1h2p5e3ks418
14 Sep 21
Regulation FD Disclosure
4:20pm
8-K
EX-99.1
avaiqgmadn
12 Dec 18
Regulation FD Disclosure
4:30pm
8-K
EX-99.1
hy3avb
1 Jun 20
Regulation FD Disclosure
6:55am
8-K
EX-10.2
aulp6c4 ytl
31 Dec 19
EyeGate Announces $5.0 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
4:05pm
8-K
EX-99.1
g09hih
9 Sep 19
Regulation FD Disclosure
6:50am
8-K
EX-10.2
1jvb32z turakt
10 Aug 21
EyeGate Announces $10.75 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
6:55am
8-K
EX-10.2
7b9a90szvejx6do
1 Feb 24
Kiora Pharmaceuticals Announces Private Placement of up to Approximately $45 Million
7:01am
8-K
EX-2.1
7iqda7hr
26 Oct 21
EyeGate adds Bayon Therapeutics’ portfolio of vision-restoring small molecules to its development pipeline
7:00am